Redbiotec Pivots Toward HSV-2 Therapies And Therapeutic Bacteria
Redbiotec has reached a new inflection point as it progresses two key programs in herpes and cancer. The company’s CEO and CSO explain how it hopes to use bacteria as a delivery system for genes or proteins to treat cancer.
You may also be interested in...
Pfizer has continued its recent deal-making spree with the acquisition of a "controlling interest" in Redvax, a spin-off from Redbiotec, a privately held Swiss biopharmaceutical company.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Two European pharmaceutical companies, UCB and Merck KGaA, are exploring artificial intelligence in different ways, the first for drug discovery and the second on a fundamental level.